

# Limitation of immune tolerance–inducing thymic epithelial cell development by Spi-B–mediated negative feedback regulation

Nobuko Akiyama,<sup>1</sup> Miho Shinzawa,<sup>1</sup> Maki Miyauchi,<sup>1</sup> Hiromi Yanai,<sup>1</sup> Ryosuke Tateishi,<sup>1</sup> Yusuke Shimo,<sup>1</sup> Daisuke Ohshima,<sup>1</sup> Koichi Matsuo,<sup>2</sup> Izumi Sasaki,<sup>3</sup> Katsuaki Hoshino,<sup>3,4,5</sup> Guoying Wu,<sup>6</sup> Shintaro Yagi,<sup>6</sup> Jun-ichiro Inoue,<sup>1</sup> Tsuneyasu Kaisho,<sup>3,4</sup> and Taishin Akiyama<sup>1</sup>

<sup>1</sup>Division of Cellular and Molecular Biology, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan

<sup>2</sup>Laboratory of Cell and Tissue Biology, Graduate School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan

<sup>3</sup>Laboratory for Immune Regulation, World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan

<sup>4</sup>Laboratory for Inflammatory Regulation, Research Center for Allergy and Immunology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

<sup>5</sup>Department of Immunology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa 761-0793, Japan

<sup>6</sup>Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan

**Medullary thymic epithelial cells (mTECs) expressing the autoimmune regulator AIRE and various tissue-specific antigens (TSAs) are critical for preventing the onset of autoimmunity and may attenuate tumor immunity. However, molecular mechanisms controlling mTEC development remain elusive. Here, we describe the roles of the transcription factor Spi-B in mTEC development. Spi-B is rapidly up-regulated by receptor activator of NF- $\kappa$ B ligand (RANKL) cytokine signaling, which triggers mTEC differentiation, and in turn up-regulates CD80, CD86, some TSAs, and the natural inhibitor of RANKL signaling, osteoprotegerin (OPG). Spi-B–mediated OPG expression limits mTEC development in neonates but not in embryos, suggesting developmental stage–specific negative feedback regulation. OPG–mediated negative regulation attenuates cellularity of thymic regulatory T cells and tumor development in vivo. Hence, these data suggest that this negative RANKL–Spi-B–OPG feedback mechanism finely tunes mTEC development and function and may optimize the trade-off between prevention of autoimmunity and induction of antitumor immunity.**

Of the various T cell types that develop in the thymus, medullary thymic epithelial cells (TECs [mTECs]) are crucial to the induction of T cell tolerance to endogenous tissues during thymic T cell development (Anderson and Takahama, 2012). Mature mTECs highly express MHC class II (MHC II) and co-stimulatory molecules, such as CD80 and CD86, and function as self-antigen-presenting cells in the thymus (Kyewski and Klein, 2006; Klein et al., 2009; Hinterberger et al., 2010). Uniquely, mature mTECs promiscuously express a wide variety of endogenous tissue-specific antigens (TSAs), including insulin, C-reactive protein, and caseins (Kyewski and Klein, 2006; Klein et al., 2009). The autoimmune regulator Aire, mutations in which cause human autoimmune diseases, is a transcription factor that is highly expressed in mature mTECs and that

enhances TSA diversity (Abramson et al., 2010). Consequently, mature mTECs promote clonal deletion and regulatory T cell (T reg cell) conversion of potentially TSA-reactive T cells; these are critical for preventing the onset of autoimmunity. Furthermore, recent studies have shown that Aire deficiency inhibits tumor growth and T reg cell accumulation in tumors (Träger et al., 2012; Malchow et al., 2013; Zhu et al., 2013), suggesting that mTECs induce immunological tolerance in tumor and normal tissues. This implies that precise regulation of mTEC–mediated tolerance may be critical for balancing prevention of


## CORRESPONDENCE

Taishin Akiyama:  
taishin@ims.u-tokyo.ac.jp  
OR

Tsuneyasu Kaisho:  
tkaisho@wakayama-med.ac.jp

Abbreviations used: 2DG, 2'-deoxyguanosine; FTOC, fetal thymus organ culture; MCA, methylcholanthrene; mTEC, medullary TEC; NIK, NF- $\kappa$ B–inducing kinase; OPG, osteoprotegerin; qPCR, quantitative RT-PCR; RANK, receptor activator of NF- $\kappa$ B; RANKL, RANK ligand; T-DMR, tissue-dependently and differentially methylated region; TEC, thymic epithelial cell; TSA, tissue-specific antigen.

© 2014 Akiyama et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons license (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).



**Figure 1. RANK signaling up-regulates Spi-B expression through an NIK-dependent pathway in mTECs.** (A) Fetal thymic stromal organ cultures (2DG-FTOCs) were prepared and stimulated with recombinant RANKL protein. Thymic lobes isolated from an E15 mouse fetus were cultured in the presence of 2DG to eliminate hematopoietic cells, yielding 2DG-FTOCs. Addition of recombinant RANKL induced mTECs expressing Aire and TSAs in 2DG-FTOCs. Bottom panels show immunohistochemical staining of 2DG-FTOC cryosections with UEA-1, a mature mTEC marker, and keratin-5 (K5) before and at days 1, 2, 3, and 4 after RANKL stimulation. Bars, 200  $\mu$ m. (B) qPCR analysis of *Spib* mRNA expression in 2DG-FTOCs at 4 d after incubation without (control) or with 1  $\mu$ g/ml recombinant RANKL. For blocking experiments (RANKL + RANK-Fc), 5  $\mu$ g/ml RANK-Fc was added to the culture medium. The values are arbitrary units (A.U.) normalized to *Gapdh* expression. (C) Expression of *Spib*, *Aire*, and *Spt1* in 2DG-FTOC at 1–4 d after incubation with 1  $\mu$ g/ml recombinant RANKL or before RANKL stimulation (day 0) were analyzed by qPCR. The values are normalized to *Gapdh* expression. (D) RANKL stimulation induces *Spib* expression in an

autoimmunity with induction of tumor immunity, but the molecular mechanisms underlying development and function of mTECs are poorly understood.

We and others previously reported that the receptor activator of NF- $\kappa$ B (RANK) ligand (RANKL) promotes development of mature mTECs (Rossi et al., 2007; Akiyama et al., 2008, 2012b; Hikosaka et al., 2008). Moreover, several signal transducers regulating NF- $\kappa$ B activation pathways, such as TNF receptor-activated factor 6 (TRAF6), NF- $\kappa$ B-inducing kinase (NIK), and the NF- $\kappa$ B family member RelB, are required for mTEC development (Burkly et al., 1995; Weih et al., 1995; Kajiura et al., 2004; Akiyama et al., 2005). Thus, RANKL probably triggers mTEC differentiation by activating NF- $\kappa$ B pathways (Akiyama et al., 2012b), but the molecular events involved remain unknown.

The Ets transcription factor family member Spi-B (Ray et al., 1992) regulates plasmacytoid dendritic cell development and function, B cell antigen receptor signaling, early T cell lineage decisions, and intestinal M cell development (Garrett-Sinha et al., 1999; Schotte et al., 2004; Dontje et al., 2006; Kanaya et al., 2012; Sasaki et al., 2012). The locus of human *SPIB* has also been associated with autoimmune primary biliary cirrhosis (Liu et al., 2010), implicating it in prevention of autoimmunity.

Here, we demonstrate that Spi-B links RANKL–NF- $\kappa$ B signaling with up-regulation of several molecules expressed in mature mTECs, including CD80, CD86, some TSAs, and osteoprotegerin (OPG), the natural inhibitor of RANKL. Moreover, we show that Spi-B–mediated OPG expression in the thymus limits the development of mature mTECs via a negative feedback regulatory circuit that may facilitate immune responses to tumors.

## RESULTS

### RANKL signaling up-regulates Spi-B expression in mTECs through an NIK-dependent pathway


We recently identified candidate transcriptional regulators of mTEC development by microarray analysis (Ohshima et al.,

2011). Spi-B was selected for further analysis because of its possible involvement in autoimmune disease (Liu et al., 2010). We first investigated whether RANKL signaling induces the expression of Spi-B in mTECs. RANKL stimulation is known to induce differentiation of mature mTECs expressing Aire, TSAs, and an mTEC marker, UEA-1 lectin ligand (Fig. 1 A) in in vitro organ culture of fetal thymic stroma (2'-deoxyguanosine [2DG]–fetal thymus organ culture [FTOC]; Rossi et al., 2007; Akiyama et al., 2008), which is prepared by depleting cells of hematopoietic origin from fetal thymus (Aichinger et al., 2012). Quantitative RT-PCR (qPCR) revealed that *Spib* mRNA was significantly up-regulated by RANKL stimulation in 2DG-FTOCs (Fig. 1 B). Addition of RANK-Fc blocked RANKL-dependent *Spib* expression (Fig. 1 B), confirming the requirement of RANKL–RANK interactions. RANKL-dependent up-regulation of *Spib* preceded that of *Aire*, the TSA *Salivary protein 1* (*Spt1*), and *UEA-1* (Figs. 1, A and C), suggesting that *Spib* is an early gene that responds to RANKL signaling.

We next investigated whether RANKL signaling induces *Spib* expression in an established mTEC line because 2DG-FTOCs contain several types of stromal cells, including TECs. This mTEC line was retrovirally transduced with RANK (RANK-TEC) because endogenous RANK expression was undetectable in the currently available mTEC lines. Stimulation with RANKL rapidly and continuously up-regulated *Spib* expression in the RANK-TECs (Fig. 1 D). These findings suggest that *Spib* expression is rapidly induced by RANKL signaling in mTECs.

Subsequently, we determined whether Spi-B is expressed in mTECs in vivo. Adult mouse thymic stroma cells (CD45<sup>+</sup> TER119<sup>−</sup>) were sorted by staining with anti-EpCAM (an epithelial cell marker) and UEA-1 and were subsequently processed for qPCR gene expression assays. The mTEC fraction (UEA-1<sup>+</sup>EpCAM<sup>+</sup>), which exhibits high RANK expression levels (Fig. 1 E), showed significantly higher levels of Spi-B expression than did the cTEC-rich fraction (UEA-1<sup>−</sup>EpCAM<sup>+</sup>)

established mTEC line. Expression of *Spib* in the RANK-mTEC line at 2 h and at 2 d after RANKL stimulation was determined by qPCR. Values are normalized to *Gapdh* expression and further normalized to the control values. (E) The UEA-1<sup>+</sup>EpCAM<sup>+</sup> CD45<sup>+</sup> TER119<sup>−</sup> (mTEC fraction), UEA-1<sup>−</sup>EpCAM<sup>+</sup> CD45<sup>+</sup> TER119<sup>−</sup> (cTEC-rich fraction), and EpCAM<sup>−</sup> CD45<sup>+</sup> TER119<sup>−</sup> (non-TEC fraction) fractions were sorted from 6-wk-old C57BL/6 mice. The expression levels of *Spib* and *Rank* in each fraction were determined by qPCR. Values are arbitrary units normalized to *Gapdh* expression. (F) qPCR analysis of expression of *Spib1* and *Spib2*, transcripts from two different promoters of *Spib*, in 2DG-FTOCs after 1–4 d of incubation with 1  $\mu$ g/ml recombinant RANKL or before stimulation (day 0). Values are normalized to *Gapdh* expression and further normalized to the control values. (G) Expression of *Spib1* and *Spib2* in thymic stromal cells of adult mice. mTEC, cTEC-rich, and non-TEC fractions were sorted from 6-wk-old C57BL/6 mice. Expression levels of *Spib1* and *Spib2* in each fraction were determined by qPCR. Values are arbitrary units normalized to *Gapdh* expression. (H) Human and mouse *Spib* genes were compared using the VISTA algorithm. The arrowhead indicates the transcriptional start site for *Spib1* (transcribed from *Spib*-P1). The CNS shows a conserved noncoding sequence upstream of the *Spib1* initiation site. The black bars (*Spib*-P1 and *Spib*-P2) indicate the promoter regions isolated for the reporter assay. After RANK-mTECs were transfected with *Spib*-P1 luciferase reporter plasmid and a  $\beta$ -galactosidase plasmid and stimulated with 1  $\mu$ g/ml recombinant RANKL, luciferase activities were determined. The fold induction was calculated on the basis of the luciferase activity of unstimulated cells. (I) Overexpression of NIK or RelB complex, but not TRAF6, activates *Spib*-P1. HEK293T cells were transfected with expression vectors encoding NIK, TRAF6, or a combination of RelB and p50 together with a *Spib*-P1 luciferase reporter plasmid or artificial NF- $\kappa$ B promoter (3 $\kappa$ B) and a  $\beta$ -galactosidase plasmid as an internal control for transfection efficiency. The 3 $\kappa$ B promoter contains three typical NF- $\kappa$ B-binding sites. The fold induction was calculated on the basis of the vector control sample. Representative data from three independent triplicate experiments are shown in the graphs. (J) RANKL-mediated *Spib* expression in 2DG-FTOCs is dependent on functional NIK. qPCR analysis of *Spib* expression in *aly/+* and *aly/aly* 2DG-FTOCs at 4 d after incubation with 1  $\mu$ g/ml recombinant RANKL was performed. Error bars represent mean  $\pm$  one SD for three independent experiments (B–H and J) or triplicate experiments (I). \*, P < 0.05; \*\*, P < 0.01; and \*\*\*, P < 0.001 (Student's *t* test).



**Figure 2. Spi-B limits development of mature mTECs and up-regulates CD80 and CD86 expression in mature mTECs.** (A) Thymic stromal cells (CD45<sup>+</sup>TER119<sup>-</sup>) among total thymic cells of 3-wk-old WT and *Spib*<sup>-/-</sup> mice were analyzed by staining with MHC II (I-A/I-E) antibody and UEA-1 lectin, an mTEC marker (left). Flow cytometric data are summarized in the graphs. The percentages of MHC II<sup>hi</sup>UEA-1<sup>+</sup> (mTEC<sup>hi</sup>), MHC II<sup>lo</sup>UEA-1<sup>+</sup> (mTEC<sup>lo</sup>), and UEA-1<sup>-</sup>MHC II<sup>+</sup> (mainly cTEC) cells among thymic stroma cells and their numbers in the thymus are shown. (B) 2DG-FTOC prepared from a



and the nonepithelial stromal cell fraction (EpCAM<sup>-</sup>; Fig. 1 E). These data were consistent with increased Spi-B expression after RANKL signaling in thymic RANK-expressing mTECs.

Next, we investigated the mechanisms regulating Spi-B expression that occur downstream of RANKL signaling. Previous studies showed that murine *Spib* is transcribed from two different promoters (Chen et al., 1998), which can be discriminated using qPCR (Bartholdy et al., 2006). RANKL stimulation selectively induced 1 of the *Spib* transcripts (*Spib1*) in 2DG-FTOC (Fig. 1 F). Moreover, *Spib1* expression was higher in mTECs than in other stromal cell fractions (Fig. 1 G). Thus, increased *Spib* expression in mTECs (Fig. 1 E) follows expression of *Spib1* but not that of *Spib2*. Because RANKL signaling selectively activates the promoter that drives *Spib1* transcription, the genomic region containing the conserved noncoding sequence upstream of the *Spib1* initiation site (Fig. 1 H) was linked to a luciferase gene for reporter assays (*Spib*-P1-luc). As expected, *Spib*-P1-luc was responsive to RANKL stimulation in the RANK-mTEC line (Fig. 1 H), suggesting that this region contains the promoter that drives *Spib* transcription.

Previous studies showed that the signal transducers TRAF6 and NIK, which mediate classical and nonclassical NF- $\kappa$ B activation pathways, respectively, are required during RANKL-mediated mTEC differentiation (Kajiura et al., 2004; Akiyama et al., 2005, 2008). Thus, we investigated whether overexpression of these two signal transducers activated *Spib*-P1 in cells. Interestingly, *Spib*-P1 was activated only in NIK-overexpressing cells (Fig. 1 I), whereas an artificial NF- $\kappa$ B promoter (3 $\kappa$ B-luc) was effectively activated by NIK or TRAF6 overexpression (Fig. 1 I). Induction of NIK activates the RelB complex (Thu and Richmond, 2010; Sun, 2012). Overexpression of the latter effectively activated the *Spib*-P1 promoter (Fig. 1 I). Moreover, a dysfunctional point mutation in *Nik* (*aly/aly* mutation) markedly diminished RANKL-mediated *Spib* expression in 2DG-FTOCs (Fig. 1 J; Shinkura et al., 1999). Thus, these data suggested that *Spib* is a target gene of RANKL-NIK-NF- $\kappa$ B signaling that promotes mTEC development


(Kajiura et al., 2004; Akiyama et al., 2008, 2012b). Therefore, we investigated the roles of Spi-B in mature mTEC development in Spi-B-deficient (*Spib*<sup>-/-</sup>) mice.

### Spi-B limits development of mature mTECs but promotes CD80 expression in mature mTECs

Adult murine mTECs are classified into subsets according to the expression levels of MHC II. mTECs expressing high MHC II levels (mTEC<sup>hi</sup>) express a wide variety of TSAs (Kyewski and Klein, 2006; Anderson and Takahama, 2012) and are considered more mature than those expressing low MHC II (mTEC<sup>lo</sup>) levels (Gray et al., 2007; Anderson et al., 2009). Flow cytometry revealed that the numbers and frequencies of total mTECs and mTEC<sup>hi</sup> were significantly increased in the absence of Spi-B (Fig. 2 A), indicating that Spi-B is a negative regulator of mature mTEC development. To confirm that expression of Spi-B in TECs, but not in thymocytes, is responsible for this phenotype, we transplanted 2DG-FTOCs from *Spib*<sup>-/-</sup> and WT fetal thymus into the kidney capsules of athymic nude mice. In these chimeric mice, the thymus comprises Spi-B-deficient thymic stroma and thymocytes derived from nude mice. mTEC<sup>hi</sup> numbers were significantly increased in the developed thymus of mice receiving *Spib*<sup>-/-</sup> 2DG-FTOCs (Fig. 2 B), indicating that Spi-B in thymic stromal cells limits the development of mTEC<sup>hi</sup> cells.


We next investigated the expression of other mTEC marker proteins in *Spib*<sup>-/-</sup> thymuses using flow cytometry. The mTEC<sup>hi</sup> subset includes Aire-expressing mTECs (Gray et al., 2007). Moreover, mTEC<sup>hi</sup> cells express high levels of co-stimulatory molecules, such as CD80, CD86, PD-L1, and CD40 (Kyewski and Klein, 2006; Klein et al., 2009; Hinterberger et al., 2010). As expected, Aire expression levels in whole thymus were increased by the lack of Spi-B (Fig. 2 C). Consistently, the number and frequency of Aire-expressing mTECs were increased in *Spib*<sup>-/-</sup> thymuses (Fig. 2 D), whereas Aire expression levels in Aire-expressing mTECs were slightly reduced by the absence of Spi-B (Fig. 2 E). Remarkably, CD80 expression was diminished in *Spib*<sup>-/-</sup> mTEC<sup>hi</sup>,

*Spib*<sup>-/-</sup> or WT fetus (six lobes each) were transplanted into the kidneys of nude mice. The grafted thymuses were analyzed by flow cytometry at 6 wk after transplantation. The numbers of MHC II<sup>+</sup>UEA-1<sup>+</sup>, MHC II<sup>hi</sup>UEA-1<sup>+</sup> (mTEC<sup>hi</sup>), MHC II<sup>lo</sup>UEA-1<sup>+</sup> (mTEC<sup>lo</sup>), and UEA-1<sup>-</sup>MHC II<sup>+</sup> (mainly cTEC) cells in the transplanted thymuses are shown. (C) Expression levels of *Aire* in WT and *Spib*<sup>-/-</sup> thymuses of 3-wk-old mice were determined by qPCR. Values are arbitrary units (A.U.) normalized to *Gapdh* expression. (D) Flow cytometric profiles of Aire-expressing mTECs in WT and *Spib*<sup>-/-</sup> TECs (left) in 3-wk-old mice. TECs (EpCAM<sup>+</sup>CD45<sup>-</sup>TER119<sup>-</sup>) were analyzed by staining with a combination of UEA-1 lectin and Aire antibody. The percentage of Aire<sup>+</sup> mTECs among TECs and cell number of Aire<sup>+</sup> mTECs in the thymus are shown in the graphs on the right. (E) Flow cytometric profiles of Aire expression in Aire-expressing mTECs of 3-wk-old WT and *Spib*<sup>-/-</sup> mice. Expression of Aire in Aire<sup>+</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>-</sup>TER119<sup>-</sup> of WT and *Spib*<sup>-/-</sup> mice was analyzed. Expression levels of Aire as means of fluorescence intensity (MFI) are summarized in the graph below. (F) Flow cytometric profiles of Aire-expressing mTECs in WT and *Spib*<sup>-/-</sup> TECs (left). TECs (EpCAM<sup>+</sup>CD45<sup>-</sup>TER119<sup>-</sup>) of 3-wk-old mice were analyzed by staining with a combination of CD80 and Aire antibodies. The percentage of Aire<sup>+</sup>CD80<sup>hi</sup> mTECs among TECs is shown in the graph on the right. (G) Flow cytometric profiles of CD80 expression in mTECs of 3-wk-old WT and *Spib*<sup>-/-</sup> mice. Expression of CD80 in mTECs expressing high levels of MHC II (MHC II<sup>hi</sup>) and mTECs expressing low levels of MHC II (MHC II<sup>lo</sup>) of WT and *Spib*<sup>-/-</sup> mice were analyzed. Expression levels of CD80 as means of fluorescence intensity are summarized in the graph on the right. (H) Flow cytometric profiles of MHC II<sup>+</sup>CD86<sup>+</sup> cells in mTECs (UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>-</sup>TER119<sup>-</sup>) of WT and *Spib*<sup>-/-</sup> mice (left). The percentage of MHC II<sup>hi</sup>CD86<sup>hi</sup> cells (left, rectangles) among mTECs is shown in the graph on the right. (I) Flow cytometric profiles of PD-L1 and CD40 expression in mTECs expressing high levels of MHC II (MHC II<sup>hi</sup>) of WT and *Spib*<sup>-/-</sup> mice. Error bars represent mean  $\pm$  one SD for four (A and D–H) or three (B and C) independent experiments. \*, P < 0.05, \*\*, P < 0.01; and \*\*\*, P < 0.001 (Student's *t* test).



**Figure 3. Spi-B promotes expressions of decoy receptor OPG and thereby limits mTEC development.** (A) Expression of *Opg*, *Rank*, *Ccl19*, *Spt1*, *Col2*, and *Csnb* in mTECs sorted from the thymuses of *Spib*<sup>-/-</sup> and WT mice was analyzed by qPCR. Salivary protein 1, collagen 2, and casein-β are TSAs promiscuously expressed in mTECs. Values are arbitrary units (A.U.) normalized to *Gapdh* expression. Per experiment, the mTECs were isolated and pooled from three WT or three *Spib*<sup>-/-</sup> mice (3–4 wk old). (B) Thymic cryosections of 3-wk-old WT and *Spib*<sup>-/-</sup> mice were immunostained with anti-OPG and UEA-1 antibodies. White arrows indicate OPG expression. Figures are representatives of three independent experiments. Bars, 200 μm. (C, left) qPCR analysis of *Opg* expression in 2DG-FTOCs at 4 d after incubation with 1 μg/ml recombinant RANKL (+RANKL) or without RANKL (control). For blocking experiments (+RANKL + RANKL-Fc), 5 μg/ml RANK-Fc was added to the culture medium. Values are arbitrary units normalized to *Gapdh* expression. (right) Expression of *Opg* in 2DG-FTOC at 1–4 d after incubation with 1 μg/ml recombinant RANKL (+RANKL) or before RANKL stimulation (day 0) was analyzed by qPCR. Values are normalized to *Gapdh* expression and further normalized to the control values. (D) qPCR analysis was performed to determine *Opg* expression levels in WT and *Spib*<sup>-/-</sup> 2DG-FTOCs at 4 d after incubation with 1 μg/ml recombinant RANKL. Values are arbitrary units normalized to *Gapdh* expression. (E) DNA methylation analysis of *Opg* in the mTEC and EpCAM<sup>+</sup> stromal cell fractions sorted from the thymuses of 3-wk-old *Spib*<sup>-/-</sup> and WT mice. Each T-DMR contains four CpG sites. The DNA methylation status of CpGs in T-DMRs is indicated as open (unmethylated) and closed (methylated) circles. Percentages of unmethylated CpGs in T-DMR are indicated under each panel. T-DMRs and the transcription start site of *Opg* are schematically shown at the bottom of the panels. Data of methylated CpGs were obtained from three independent pairs of *Spib*<sup>-/-</sup> and WT mice and are summarized in the graphs on the right. (F) Typical flow cytometric profiles of TECs prepared from 3-wk-old *Opg*<sup>-/-</sup> and *Spib*<sup>-/-</sup>*Opg*<sup>-/-</sup> mice (C57BL/6 background). Flow cytometric analyses of *Opg*<sup>-/-</sup> and *Spib*<sup>-/-</sup>*Opg*<sup>-/-</sup> thymic stromal cells are summarized in the graphs. The percentage of MHC II<sup>+</sup>UEA-1<sup>+</sup>,

MHC II<sup>hi</sup>UEA-1<sup>+</sup> (mTEC<sup>hi</sup>), MHC II<sup>lo</sup>UEA-1<sup>+</sup> (mTEC<sup>lo</sup>), and UEA-1<sup>-</sup>MHC II<sup>+</sup> (mainly cTEC) cells among thymic cells and their cell numbers are shown. Red and green dotted lines indicate data from 3-wk-old *Spib*<sup>-/-</sup> mice and WT mice, respectively. Error bars represent mean ± one SD for four (A and F) or three (C–E) independent experiments. \*, P < 0.05, \*\*, P < 0.01; and \*\*\*, P < 0.001 (Student's *t* test).



**Figure 4. Spi-B-OPG system fine-tunes mTEC development from neonates via negative feedback regulation.** (A) Flow cytometric analysis of mTECs prepared from WT and *SpiB*<sup>-/-</sup> mice at E15.5 (WT, *n* = 9; and *SpiB*<sup>-/-</sup>, *n* = 6; *P* > 0.05), at E17.5 (WT, *n* = 8; and *SpiB*<sup>-/-</sup>, *n* = 8; *P* > 0.05), PN1 (WT, *n* = 7; and *SpiB*<sup>-/-</sup> mice, *n* = 9; *P* = 1.52 × 10<sup>-6</sup>), and PN8 (WT, *n* = 4; and *SpiB*<sup>-/-</sup>, *n* = 5; *P* = 3.03 × 10<sup>-5</sup>). Typical flow cytometric profiles of MHC II (I-A/I-E) and UEA-1 lectin-positive cells, which are also EpCAM<sup>+</sup>, among thymic stroma cells (CD45<sup>+</sup>TER119<sup>-</sup>) are shown. Percentages of mTECs among thymic stroma cells are summarized in the graph on the right. (B) Immunostaining of thymic sections from WT and *SpiB*<sup>-/-</sup> mice at E17.5, PN1, and PN8. Thymic cryosections were immunostained with keratin-5 and UEA-1 lectin antibodies. Figures are representative of three independent experiments. Bars, 200 μm. (C) Expression levels of *Aire* in whole thymus from WT and *SpiB*<sup>-/-</sup> mice at E17.5 (WT, *n* = 4; and *SpiB*<sup>-/-</sup>, *n* = 3; *P* > 0.1), PN1 (WT, *n* = 7; and *SpiB*<sup>-/-</sup>, *n* = 9; *P* = 7.4 × 10<sup>-4</sup>), and PN8 (WT, *n* = 4; and *SpiB*<sup>-/-</sup>, *n* = 4; *P* = 0.045) were determined by qPCR. The values are arbitrary units (A.U.) normalized to *36B4* expression. (D) Flow cytometric profiles of thymic cells prepared at E15.5 (WT, *n* = 5; and *Opg*<sup>-/-</sup>, *n* = 4; *P* > 0.5), E17.5 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 4; *P* = 0.0022), PN1 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 6; *P* = 4.91 × 10<sup>-8</sup>), and PN8 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 4; *P* = 1.94 × 10<sup>-8</sup>). Typical flow cytometric profiles of MHC II (I-A/I-E) and UEA-1 lectin-positive cells, which are also EpCAM<sup>+</sup> (not depicted), among thymic stroma cells (CD45<sup>+</sup>TER119<sup>-</sup>) are shown on the left. Percentages of mTECs among thymic stroma cells are summarized in the graph on the right. (E) Flow cytometric profiles of thymic cells prepared at E15.5 (WT, *n* = 5; and *Opg*<sup>-/-</sup>, *n* = 4; *P* > 0.2), E17.5 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 4; *P* > 0.8), PN1 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 6; *P* = 1.19 × 10<sup>-9</sup>), and PN8 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 4; *P* = 1.21 × 10<sup>-7</sup>). Typical flow cytometric profiles of CD80- and UEA-1 lectin-positive cells, which are also EpCAM<sup>+</sup> (not depicted), among thymic stroma cells (CD45<sup>+</sup>TER119<sup>-</sup>) are shown on the left. Percentages of CD80<sup>hi</sup> mature mTECs in thymic stroma cells are summarized in the graph on the right. (F and G) qPCR analysis of *Opg* in mature mTECs (CD80<sup>hi</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>), immature mTECs (CD80<sup>lo</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>), and cTECs (CD80<sup>lo</sup>UEA-1<sup>-</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>) sorted from thymuses of WT mice at PN1 (cTECs, *n* = 6; immature mTECs, *n* = 7; and mature mTECs, *n* = 5). Values are arbitrary units normalized to *36B4* expression. Per experiment, the mTECs were isolated from three neonates and pooled for RNA preparation. (G) qPCR analysis of *Opg* in mature mTECs (CD80<sup>hi</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>) sorted from thymuses of WT mice at E17.5 (*n* = 3), PN1 (*n* = 5), PN4 (*n* = 4), and PN14 (*n* = 4). Values are arbitrary units normalized to *36B4* expression. Per experiment, the mTECs were isolated from several embryos and neonates and pooled for RNA preparation. Error bars represent mean ± one SD. (H) qPCR analysis of *Spib* in immature mTECs (CD80<sup>lo</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>) and mature mTECs (CD80<sup>hi</sup>UEA-1<sup>+</sup>EpCAM<sup>+</sup>CD45<sup>+</sup>TER119<sup>-</sup>) sorted from thymuses of *Opg*<sup>-/-</sup> and WT mice at PN1 (*n* = 3). Per experiment, mTECs were isolated from several neonates and pooled for RNA preparation. Values are arbitrary units normalized to *36B4* expression. (F and H) Error bars represent mean ± one SD for four independent experiments. \*, *P* < 0.05, \*\*, *P* < 0.01; and \*\*\*, *P* < 0.001 (Student's *t* test).



including Aire-expressing mTECs (Fig. 2, F and G). Moreover, mTECs expressing high levels of CD86 were significantly reduced in *SpiB*<sup>-/-</sup> mice (Fig. 2 H). In contrast, expression of the other co-stimulatory molecules, PD-L1 and CD40, was not affected by the absence of Spi-B (Fig. 2 I), suggesting that Spi-B selectively up-regulates CD80 and CD86 among co-stimulatory molecules in mTEC<sup>hi</sup> cells. Altogether, these data demonstrated two distinct novel functions of Spi-B during mTEC development: Spi-B limits mature mTEC development and promotes expression of co-stimulatory molecules CD80 and CD86 in mTECs.

### Spi-B facilitates expression of OPG and some TSAs in mTECs

Because Spi-B may selectively regulate gene expression in mTECs, we subsequently identified other genes that are regulated by Spi-B in mTECs. We sorted mTEC fractions (EpCAM<sup>+</sup> UEA-1<sup>+</sup>) from *SpiB*<sup>-/-</sup> and WT mice and investigated gene expression using qPCR. Indeed, expression of the TSAs *Spt1* and *Col2* was significantly reduced in *SpiB*<sup>-/-</sup> mTEC fractions compared with those in WT mTEC fractions (Fig. 3 A). Thus, Spi-B may facilitate the expression of some TSA members by an Aire-independent mechanism. Notably, the expression of OPG was significantly reduced in *SpiB*<sup>-/-</sup> mTECs (Fig. 3 A), and reduced OPG protein expression was confirmed by immunohistochemical staining of thymic sections (Fig. 3 B). OPG competitively inhibits RANKL–RANK interactions as a decoy receptor of RANKL (Leibbrandt and Penninger, 2008), thereby inhibiting mTEC development (Hikosaka et al., 2008). Because this inhibitory effect (Fig. 2) may relate to reduced OPG expression, we further characterized Spi-B-dependent OPG expression in mTECs.

As expected, *Opg* mRNA expression was induced by RANKL signaling in 2DG-FTOCs (Fig. 3 C). RANKL stimulation consecutively induced *SpiB* and *Opg* expression (compare Fig. 3 C with Fig. 1 C). RANKL-dependent *Opg* expression was significantly reduced in the absence of Spi-B in 2DG-FTOCs (Fig. 3 D). These data suggested that RANKL signaling up-regulates *SpiB* expression and promotes expression of its own inhibitor, OPG, in mTECs.

Subsequently, we investigated the mechanism regulating *Opg* expression via Spi-B in mTECs. Because Spi-B overexpression did not activate the putative proximal promoter of *Opg* in reporter assays (not depicted), Spi-B was expected to control *Opg* transcription without directly binding to the proximal promoter of the gene. Thus, we analyzed CpG methylation of *Opg* in sorted mTEC fractions. Initially, we observed two CpG-rich regions that were hypomethylated in mTECs compared with EpCAM<sup>-</sup> thymic stromal cells (Fig. 3 E), suggesting that *Opg* is tissue-dependently and differentially methylated (Yagi et al., 2008) in these regions (referred to as tissue-dependently and differentially methylated region [T-DMR] #1 and T-DMR #2). T-DMRs were hypermethylated in *SpiB*<sup>-/-</sup> mTECs compared with control mTECs (Fig. 3 E). Thus, Spi-B expression in mTECs leads to either demethylation of CpG sites or maintenance of their hypomethylated states in *Opg*, which may enhance *Opg* expression.


Moreover, we genetically verified that enhancement of mTEC development in *SpiB*<sup>-/-</sup> mice was dependent on OPG expression. As reported earlier (Hikosaka et al., 2008), OPG-deficient (*Opg*<sup>-/-</sup>) mice showed enhanced development of mTECs (Fig. 3 F) compared with WT controls (Figs. 2 A and 3 F [green lines]). Indeed, mTEC development was similar between *Opg*<sup>-/-</sup> mice and Spi-B and OPG double-deficient (*SpiB*<sup>-/-</sup>*Opg*<sup>-/-</sup>) mice (Fig. 3 F). Thus, Spi-B does not attenuate mTEC development in the absence of OPG, strongly suggesting that the difference in mTEC development between WT and *SpiB*<sup>-/-</sup> mice was caused by differential expression of OPG.

### Spi-B-mediated negative feedback regulation of RANKL signaling initiates perinatally, limiting mTEC development

Aire-expressing mTECs in the perinatal period are essential and sufficient for establishment of long-lasting self-tolerance (Guerau-de-Arellano et al., 2009). Therefore, we investigated mTEC development in embryonic and neonatal *SpiB*<sup>-/-</sup> mice. Flow cytometric analyses of embryonic day (E) 15.5, E17.5, postnatal day (PN) 1, and PN8 thymuses revealed incremental development of mTECs (MHC II<sup>+</sup>UEA-1<sup>+</sup>) in *SpiB*<sup>-/-</sup> PN1 and PN8 mice, but not in E15.5 and E17.5 mice (Fig. 4 A). Immunohistochemical analysis confirmed enhanced development of mTECs in postnatal *SpiB*<sup>-/-</sup> thymuses (Fig. 4 B). Moreover, Aire expression levels in mature mTECs were significantly increased only in postnatal *SpiB*<sup>-/-</sup> thymuses (Fig. 4 C). Thus, negative regulation of mTEC development by Spi-B characteristically starts perinatally. Although an increment in mTEC number in response to a lack of OPG has been reported only in adult mice (Hikosaka et al., 2008), OPG function in embryonic and neonatal mTEC development remained unknown. We therefore investigated whether OPG attenuates mTEC development in a developmental stage-dependent manner, similar to Spi-B. Indeed, mTEC development was not influenced by OPG deficiency in E15.5 thymuses and minimally enhanced in E17.5 *Opg*<sup>-/-</sup> thymuses (Fig. 4 D). In contrast, mTEC development was markedly enhanced in PN1 and PN8 *Opg*<sup>-/-</sup> mice (Fig. 4 D). In embryonic and neonatal thymus, CD80 is a more expedient marker for mature mTECs than MHC II. Consistently, CD80<sup>hi</sup> mature mTECs were increased in *Opg*<sup>-/-</sup> PN1 and PN8, but not in E15.5 and E17.5 mice (Fig. 4 E). Overall, these data suggested that the negative regulation of mature mTEC development by the Spi-B–OPG system is initiated perinatally. We subsequently identified the stromal cell type that expresses *Opg* using qPCR. We found that *Opg* is expressed in CD80<sup>hi</sup> mature mTECs in PN1 mice (Fig. 4 F). Interestingly, *Opg* expression levels in mature mTECs were significantly up-regulated perinatally and plateaued in neonatal thymuses (Fig. 4 G). This may explain the stage-dependent negative regulation of mTEC development by OPG and implies a qualitative change in mature mTECs during the perinatal period.

We confirmed the RANKL–RANK–Spi-B–OPG–RANKL feedback loop in the perinatal period. Given that





**Figure 5. OPG attenuates TSA expressions and frequency of T reg cells in the thymus.** (A) Expression of *Aire*, *Spt1*, *Col2*, and *Csnb* in the whole thymus of *Opg*<sup>-/-</sup> and WT mice was analyzed by qPCR. \*,  $P < 0.05$ ; and \*\*,  $P < 0.01$  (Student's *t* test). Values are arbitrary units (A.U.) normalized to *Gapdh* expression. Error bars represent mean  $\pm$  one SD for three independent experiments. (B) Flow cytometric analysis of thymocytes of WT and *Opg*<sup>-/-</sup> mice at PN1 (WT,  $n = 3$ ; and *Opg*<sup>-/-</sup>,  $n = 3$ ), PN3 (WT,  $n = 8$ ; and *Opg*<sup>-/-</sup>,  $n = 5$ ), PN8 (WT,  $n = 6$ ; and *Opg*<sup>-/-</sup>,  $n = 6$ ), and PN18 (WT,  $n = 5$ ; and *Opg*<sup>-/-</sup>,  $n = 5$ ).

such a negative feedback loop exists, the absence of OPG would enhance Spi-B expression in mTECs by increasing RANKL signaling. Indeed, Spi-B expression was significantly enhanced in *Opg*<sup>-/-</sup> mTECs at PN1 (Fig. 4 H). Interestingly, Spi-B was expressed in both CD80<sup>lo</sup> immature mTECs and CD80<sup>hi</sup> mature mTECs (Fig. 4 H) and was also up-regulated in the absence of OPG in both mTEC types, suggesting that RANKL signaling rapidly induces Spi-B in immature mTECs before promoting differentiation into mature mTECs. Cumulatively, these data strongly suggested that Spi-B-mediated *Opg* expression attenuates the development of mTECs by a negative feedback regulation of RANKL signaling.

### Thymic stromal OPG attenuates cellularity of T reg cells in the thymus

We subsequently determined whether this negative regulation via RANKL–Spi-B–OPG influences mTEC-mediated thymic functions. We investigated the effects of abolishing this negative feedback loop in *Opg*<sup>-/-</sup> mice rather than *Spib*<sup>-/-</sup> mice because Spi-B reduces expression of CD80, CD86, and some TSAs in mTECs (Figs. 3 and 4). As reported earlier (Khan et al., 2014), expression levels of TSAs and Aire were significantly increased in *Opg*<sup>-/-</sup> thymuses (Fig. 5 A). Because mature mTECs promote T reg cell development as self-antigen-presenting cells (Hinterberger et al., 2010; Lei et al., 2011; Cowan et al., 2013; Malchow et al., 2013) and an increase in mTEC cellularity enhances thymic T reg cell development (Hauri-Hohl et al., 2014), we investigated whether OPG deficiency facilitates T reg cell development in the thymus. Indeed, numbers and frequency of Foxp3<sup>+</sup> T reg cells were significantly increased in thymuses of neonatal and young *Opg*<sup>-/-</sup> mice (Fig. 5 B). Moreover, the frequency of thymic T reg cell precursors (CD4<sup>+</sup>CD8<sup>-</sup>Foxp3<sup>-</sup>GITR<sup>+</sup>CD25<sup>+</sup>; Lio and Hsieh, 2008) was increased in *Opg*<sup>-/-</sup> thymuses (Fig. 5 C). In vitro FTOC experiments in which mTECs and T reg cells develop by endogenous signaling suggested that the increase in T reg cells by OPG deficiency is caused in a thymus-intrinsic manner (Fig. 5 D). Fetal thymic stroma transplantation experiments indicated that OPG deficiency in thymic stromal cells caused an increment of T reg cell frequency


in thymuses, whereas the increase in splenic T reg cells was not significant (Fig. 5 E). Overall, these data supported the idea that negative feedback regulation via RANKL–Spi-B–OPG attenuates mTEC-mediated thymic generation of T reg cells, although it is possible that more T reg cells are retained in the *Opg*<sup>-/-</sup> thymus.

### Thymic stromal OPG attenuates tumor incidence and growth and facilitates humoral immune responses to tumors

Because negative feedback regulation of mTEC development via RANKL–Spi-B–OPG is initiated perinatally (Figs. 4 and 5), establishing long-term self-tolerance by Aire-expressing mTECs (Guerau-de-Arellano et al., 2009), we investigated the role of this negative regulation in modulation of immunological tolerance in vivo. Recent studies suggested that Aire-expressing mTECs impede antitumor immunity (Träger et al., 2012; Malchow et al., 2013; Zhu et al., 2013). Therefore, we speculated that this feedback regulation may contribute to antitumor immunity by attenuating mTEC-dependent tolerance to tumor-derived antigens. We tested this hypothesis in mouse carcinogen-induced tumor and tumor transplantation models. To exclude any other effects caused by increased RANKL activity, we initially adoptively transplanted *Opg*<sup>-/-</sup> 2DG-FTOCs (BALB/c) into kidney capsules of BALB/c nude mice (Leibbrandt and Penninger, 2008; Akiyama et al., 2012a). A limited dose of the carcinogenic polycyclic aromatic hydrocarbon, methylcholanthrene (MCA), was injected into chimeric nude mice that had received *Opg*<sup>-/-</sup> 2DG-FTOCs (*Opg*<sup>-/-</sup>/nude) and control mice that had received WT 2DG-FTOCs. Tumor incidence was significantly increased in *Opg*<sup>-/-</sup>/nude mice compared with control mice (Fig. 6 A), indicating that thymic stromal OPG limits MCA-dependent tumor incidence in vivo.

After congenic mouse tumor cells were subcutaneously transferred into nude recipients, tumor growth was significantly increased in *Opg*<sup>-/-</sup>/nude compared with WT/nude mice (Fig. 6 B). Tumor-infiltrating T cells were reduced in tumors of *Opg*<sup>-/-</sup>/nude mice (Fig. 6 C). In addition, T reg cell numbers were significantly increased in the draining lymph nodes of these mice (Fig. 6 D). Titers of antitumor cell

Typical flow cytometric profiles at PN18 are shown on the left. Percentages of Foxp3<sup>+</sup>CD25<sup>+</sup> in CD4SP are summarized in the graph on the right. P-values were determined by Student's *t* test between *Opg*<sup>-/-</sup> and WT mice: \*\*, *P* < 0.01; \*\*\*, *P* < 0.001 (*P* = 3.6 × 10<sup>-4</sup> at PN8 and *P* = 4.6 × 10<sup>-3</sup> at PN18). Error bars represent mean ± one SD. T reg cell numbers are shown in the graphs below. P-values were determined by Student's *t* test between *Opg*<sup>-/-</sup> and WT mice: \*\*, *P* < 0.01 (*P* = 0.052 at PN8 and *P* = 4.2 × 10<sup>-3</sup> at PN18). (C) Flow cytometric analysis of thymocytes of WT and *Opg*<sup>-/-</sup> mice at PN20 (WT, *n* = 8; and *Opg*<sup>-/-</sup>, *n* = 8). The percentages of GITR<sup>+</sup>CD25<sup>+</sup> in Foxp3<sup>-</sup>CD4SP and numbers of GITR<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>-</sup>CD4SP are summarized in the graphs. P-values were determined by Student's *t* test between *Opg*<sup>-/-</sup> and WT mice: \*, *P* = 0.036; \*\*\*, *P* = 8.1 × 10<sup>-4</sup>. (D) mTECs and T reg cells of in vitro FTOC from WT and *Opg*<sup>-/-</sup> mice were analyzed by flow cytometry. Percentages of mTECs in stroma cells (CD45<sup>-</sup>TER119<sup>-</sup>) and T reg cells in CD4SP cells and numbers of mTECs and T reg cells per thymic lobe in WT and *Opg*<sup>-/-</sup> FTOC are summarized in the graphs (WT FTOC, *n* = 4; and *Opg*<sup>-/-</sup> FTOC, *n* = 3). The fetal thymuses of WT or *Opg*<sup>-/-</sup> mice were cultured for 7 d. Per experiment, FTOCs from three to four embryos were pooled. Cell numbers per thymic lobe were exhibited in graphs. P-values were determined by Student's *t* test between *Opg*<sup>-/-</sup> and WT mice: \*, *P* = 0.036 for Foxp3<sup>+</sup> Treg; \*, *P* = 0.013 for mTEC; \*\*\*, *P* = 1.3 × 10<sup>-4</sup> for Foxp3<sup>+</sup> Treg; and \*\*\*, *P* = 4.1 × 10<sup>-4</sup> for mTEC. (E) 2DG-FTOCs prepared from *Opg*<sup>-/-</sup> or WT fetuses were transplanted into the kidney of nude mice (*Opg*<sup>-/-</sup>/nude or WT/nude). The grafted thymuses and spleen were analyzed by flow cytometry 8 wk after transplantation. Typical flow cytometric profiles are shown at the top. The ratios of CD4SP cells to total thymocytes, Foxp3<sup>+</sup>CD25<sup>+</sup> cells to CD4SP cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells to splenocytes, and Foxp3<sup>+</sup>CD4<sup>+</sup> T cells to splenocytes are summarized in the graphs (WT/nude, *n* = 4; and *Opg*<sup>-/-</sup>/nude, *n* = 3). P-values were determined by Student's *t* test between *Opg*<sup>-/-</sup> and WT mice: \*, *P* < 0.05. (B–E) Black bars indicate mean values.



**Figure 6. OPG expressed in thymic stromal cells attenuates tumor development and growth.** (A) Chimeric nude mice receiving *Opg*<sup>-/-</sup> or WT 2DG-FTOCs were examined once a week for tumor development after MCA injection. The red line indicates the tumor-free rate of the chimeric nude mice receiving *Opg*<sup>-/-</sup> 2DG-FTOCs ( $n = 14$ ), and the black line indicates that of chimeric mice receiving WT 2DG-FTOCs ( $n = 13$ ).  $P = 0.033$ : log-rank test between *Opg*<sup>-/-</sup> and WT chimeric mice sets regarding the tumor-free rate. (B) Tumor cells (Meth A; female, BALB/c background) were subcutaneously transferred to nude mice receiving *Opg*<sup>-/-</sup> (tumor → *Opg*<sup>-/-</sup>/nude;  $n = 7$ ) or WT 2DG-FTOCs (tumor → WT/nude;  $n = 11$ ). The left panel shows a typical image of tumors that developed in these mice. Tumor volumes were measured on days 10, 12, and 15 (middle graph) after tumor transfer. Asterisks indicate statistical significance: \*,  $P < 0.05$  (Student's *t* test). Error bars represent one SEM. Tumor weight was measured after sacrificing the mice (right graph); asterisk indicates significant difference by Mann-Whitney *U* test: \*,  $P < 0.05$ . (C) Tumors developed from Meth A cells were analyzed. Tumor-infiltrating lymphocytes in nude mice receiving *Opg*<sup>-/-</sup> (tumor → *Opg*<sup>-/-</sup>/nude) or WT 2DG-FTOC (tumor → WT/nude) were analyzed by flow cytometry. The number of CD4<sup>+</sup> T and CD8<sup>+</sup> T cells in 1 g of tumor from nude mice receiving *Opg*<sup>-/-</sup> 2DG-FTOCs (tumor → *Opg*<sup>-/-</sup>/nude) and WT 2DG-FTOCs (tumor → WT/nude) was determined on day 15 after tumor cell (Meth A) transfer. Asterisks indicate statistical significance: \*,  $P < 0.05$  (Student's *t* test). Error bars represent mean ± one SD for the indicated number of independent experiments (WT,  $n = 5$ ; and KO,  $n = 4$ ). (D) The ratio of Foxp3<sup>+</sup>CD25<sup>+</sup> cells to CD4<sup>+</sup> cells in the lymph nodes of nude mice receiving *Opg*<sup>-/-</sup> (tumor → *Opg*<sup>-/-</sup>/nude) or WT 2DG-FTOCs (tumor → WT/nude) was determined on day 15 after tumor cell (Meth A) transfer. Asterisks indicate statistical significance: \*\*,  $P < 0.01$  (Student's

*t* test). Error bars represent mean ± one SD for the indicated number of independent experiments (WT,  $n = 11$ ; and KO,  $n = 7$ ). (E) Serum antibodies obtained from the nude mice receiving *Opg*<sup>-/-</sup> (tumor → *Opg*<sup>-/-</sup>/nude) or WT 2DG-FTOCs (tumor → WT/nude) were analyzed for tumor reactivity after tumor cell (Meth A) transfer. Meth A cells were immunostained with mouse sera (left: green, sera; red, propidium iodide for nuclear staining). Immunostaining data of Meth A with sera from tumor-transplanted mice are shown in the two top panels. Immunostaining data with WT/nude sera (without tumor transplantation) and nude sera (without transplantation of 2DG-FTOCs and tumor) are shown in bottom panels. Data are representative of three independent experiments. Western blot analysis of Meth A cell lysate using the serum from tumor → *Opg*<sup>-/-</sup>/nude or WT tumor → WT/nude mice (middle). Cell numbers of Meth A loaded as cell lysate are indicated at the top of the panels. Data are representative of three independent experiments. Arrows indicate protein bands that were reduced or disappeared in Western blots using sera of *Opg*<sup>-/-</sup>/nude mice receiving tumors. Molecular masses (kilodaltons) are indicated between the two panels. The intensity of each band indicated by a green arrow was quantified and normalized to tubulin levels (right graph). Error bars represent mean ± one SD for three independent experiments. \*,  $P < 0.05$  (Student's *t* test). Bars: (B) 1 cm; (E) 50 μm.

antibodies evoked by tumor cell transplantation (determined by immunocytochemistry) were decreased in the serum of tumor-transplanted *Opg*<sup>-/-</sup>/nude mice compared with those in

WT/nude control mice (Fig. 6 E), suggesting weaker humoral immune responses to tumors in the former. Notably, the kinds of tumor-derived proteins recognized by serum antibodies



upon Western blotting were also reduced in tumor-transplanted *Opg*<sup>-/-</sup> nude mice (Fig. 6 E, arrows), implying that TCR repertoires against tumor-derived proteins were decreased by the absence of OPG in thymic stroma. Thus, OPG expression in thymic stromal cells enhances immune responses to and limits the growth of tumors. These data further indicated that negative regulation via RANKL–Spi-B–OPG fine-tunes induction of mTEC-mediated tolerance and may ensure immune responses to tumors.

## DISCUSSION

Although RANKL signaling is known to trigger differentiation of mature mTECs, molecular events linking RANKL signaling to the expression of molecules regulating mTEC functions have been largely unexplored. Here, we demonstrated that Spi-B expression links RANKL–NF- $\kappa$ B signaling with the expression of CD80, CD86, some TSAs, and OPG, implying a key regulatory role for Spi-B in mTECs. Interestingly, Spi-B deficiency did not affect the expression of Aire, MHC II, PDL1, or CD40, which are up-regulated in mature mTECs. This suggests that other unidentified mechanisms must regulate the expression of these molecules downstream of RANKL–NF- $\kappa$ B signaling.

Spi-B regulates high expression of CD80 and CD86 in mature mTECs, suggesting its positive role in mTEC-mediated function. Interestingly, Spi-B, CD80, and NF- $\kappa$ B1 have been associated with primary biliary cirrhosis (Liu et al., 2010; Mells et al., 2011), implying that Spi-B-mediated CD80 expression is correlated to the onset of autoimmunity.

Regulation of gene expression by Spi-B in mTECs remains unclear. However, the nearest homologue of Spi-B, PU.1, reportedly induces nucleosome remodeling and H3K4 monomethylation (Heinz et al., 2010). These epigenetic events are usually associated with changes in DNA methylation (Jones and Baylin, 2007). Given that Spi-B promotes demethylation of T-DMRs in *Opg*, Spi-B may exert epigenetic controls over gene expression in mTECs. Genome-wide epigenetic and expression studies of *Spib*<sup>-/-</sup> mTECs may verify this hypothesis in future.

The mechanisms that activate self-tolerance by mTECs require stochastic encounters between self-reactive T cells and mature mTECs or dendritic cells that receive TSAs from mTECs. This mechanism may be inherently imperfect (Bouneaud et al., 2000) because of its stochasticity. The negative feedback regulation described herein ensures inadequacy of mTEC-dependent tolerance and could mediate detrimental effects by increasing the prevalence of autoreactive T cells. However, our data suggest that this negative regulation may contribute to tumor immunity and may optimize the trade-off between prevention of autoimmunity and induction of tumor immunity. Future analyses of this regulatory mechanism will promote understanding of tumor immunosurveillance and may lead to the development of new therapeutic approaches for cancer.

## MATERIALS AND METHODS

**Mice.** *Spib*<sup>-/-</sup> mice were established on a C57BL/6 background (Sasaki et al., 2012). The C57BL/6, BALB/cA, BALB/cA nude/nude, *aly*+, and *aly/aly* mice were obtained from CLEA Japan. The *Opg*<sup>-/-</sup> mice have been described previously (Mizuno et al., 1998). The *Opg*<sup>-/-</sup> mice on a BALB/cA background were prepared by backcrossing with BALB/cA mice for 10 generations. Littermates or age-matched WT mice from the same colonies as the mutant mice were used as controls. All mice were maintained under specific pathogen-free conditions and were handled in accordance with the Guidelines for Animal Experiments of the Institute of Medical Science, The University of Tokyo (Tokyo, Japan). E0.5 was defined as the first morning a vaginal plug was observed. Pregnant female mice were checked every morning and evening, and discovery of new pups was marked as day 1.

**Antibodies and reagents.** Rabbit anti-mouse keratin-5 antibody was purchased from Covance. Biotinylated UEA-1 was obtained from Vector Laboratories. The APC-Cy7-conjugated rat anti-mouse CD45, PE-Cy7-conjugated TER119, and PE-conjugated anti-mouse EpCAM (G8.8) antibodies were obtained from BD or BioLegend. The PE-conjugated rat anti-CD45, PE-conjugated mouse TER-119, FITC-conjugated mouse MHC II (M5/114.15.1), and APC-conjugated Aire antibodies were obtained from eBioscience. PE-conjugated CD80, CD86, CD40, and PD-L1 antibodies, purified anti-mouse CD16/32, FITC-conjugated anti-mouse EpCAM (G8.8), APC-Cy7-conjugated CD4, PE-Cy7-conjugated CD8, and APC-conjugated GTR antibodies were obtained from BioLegend. PE-conjugated CD8, FITC-conjugated CD4, and FITC-conjugated CD3e antibodies were obtained from BD. PE-conjugated anti-Foxp3 (FJK-16s) was purchased from eBioscience. 7-aminoactinomycin D and recombinant mouse RANKL were purchased from Wako Pure Chemical Industries. Anti-mouse OPG antibody was purchased from R&D Systems. A RANK-Fc chimera was obtained from Sigma-Aldrich. Alexa Fluor 546-conjugated streptavidin and Alexa Fluor 488-conjugated anti-rabbit IgG were obtained from Invitrogen.

**Flow cytometric analysis and cell sorting.** Whole thymus was used to prepare a single-cell suspension by digestion in RPMI 1640 medium containing collagenase/disperse (Roche) and DNase I (Sigma-Aldrich). Dead cells were excluded from the analysis after 7-aminoactinomycin D staining. After the Fc-receptor was blocked with CD16/32 antibody, the cells were stained with the indicated antibodies. For the analysis of T reg cells, thymocytes were prepared and used for nuclear staining according to the supplier's protocol (Foxp3 staining buffer set; eBioscience) and analyzed using a fluorescence-activated cell sorter (Epics XL [Beckmann Coulter] or Canto II [BD]). The single-cell suspension was separated using a Percoll gradient to obtain a TEC-rich fraction, which was stained with anti-CD45, anti-TER-119, anti-EpCAM, and UEA-1 antibodies and sorted using a cell sorter (Aria; BD).

**FTOC.** Thymic lobes were isolated from E15 embryos and were cultured on Nucleopore filters (Whatman) placed in R10 medium containing RPMI 1640 (Invitrogen) supplemented with 10% FBS (Equitech-Bio), 2 mM L-glutamine (Wako Pure Chemical Industries), 100 U/ml penicillin (Banyu Pharmaceutical), 100  $\mu$ g/ml streptomycin (Meiji Seika Kaisha), and 50  $\mu$ M 2-mercaptoethanol (Wako Pure Chemical Industries). FTOCs proceeded for 7 d and were subsequently analyzed by flow cytometry to investigate mTEC and T reg cell development in vitro. To isolate fetal thymic stromal (2DG-FTOC) cells, thymic lobes were cultured in the presence of 1.35 mM 2DG (Sigma-Aldrich) for 4 d. In some experiments, the 2DG-FTOC cells were further cultured in R10 with 1  $\mu$ g/ml recombinant RANKL. For the blocking experiments, a RANK-Fc chimera (5  $\mu$ g/ml) was added to the medium. For each day indicated after ligation, 2DG-FTOC was recovered and used for the analyses. For the transplantation experiments, the 2DG-FTOC was further cultured for 1 d without 2DG to eliminate 2DG before transplantation.

**Transplantation of 2DG-FTOC into nude mice and tumor development.** 2DG-FTOCs (six lobes each) were transplanted to the kidney capsule of 6-wk-old female nude mice. For tumor transfer experiments, Meth

A ( $5 \times 10^6$  cells) was injected subcutaneously into the nude mice receiving 2DG-FTOC at 6 wk after transplantation. Tumor sizes were measured on days 10, 12, and 15 after transplantation. At day 15, the recipient mice were killed, and the inguinal lymph nodes were prepared for flow cytometric analysis. For the carcinogen-induced model, 50  $\mu$ g MCA was injected subcutaneously into nude mice receiving 2DG-FTOC.

**Histopathology and immunohistochemistry.** For immunohistochemistry, tissues were embedded in OCT compound (Sakura) and frozen in liquid nitrogen. Cryostat sections (6- $\mu$ m thick) were fixed with ice-cold acetone and incubated with primary antibody for 1 h at room temperature. The slides were subsequently incubated with secondary antibody for 40 min at room temperature. For immunostaining of Meth A cells, cells were fixed with methanol and incubated with serum (100 $\times$  dilution) for 1 h at room temperature and then incubated with secondary antibody (anti-mouse IgG-Alexa Fluor 488) and 1  $\mu$ g/ml propidium iodide for 40 min at room temperature. Confocal color images were obtained using an FV1000D (Olympus) at 20 or 60 (Fig. 6 E) magnification and Fluoview software (Olympus).

**qRT-PCR.** Total RNA was extracted using an RNeasy micro kit (QIAGEN) or TRIzol (Invitrogen) and was subjected to random-primed reverse transcription using a Primescript II first strand cDNA synthesis kit (Takara Bio Inc.). Real-time qPCR was performed using an ABI PRISM 7300 Sequence Detection System (Applied Biosystems) and SYBR Green Master Mix (Roche or TOYOBO). The primers used were *36B4*: 5'-TCCAG-GCTTTGGGCATCA-3' and 5'-CTTTATCAGCTGCACATCACT-3'; *Gapdh*: 5'-ACCATGTAGTTGAGGTCAATGAAGG-3' and 5'-GGT-GAAGGTCGGTGTGAACG-3'; *Spib*: 5'-CTGCAAGCCCTTCAGTT-ACC-3' and 5'-AAAGGCAGCAGTAGCAGGAT-3'; *Aire*: 5'-GGTCT-GTTGGACTCTGCCCTG-3' and 5'-TGTGCCACGACGGAGGTGAG-3'; *Spt1*: 5'-GTGTTGCTTGGTGTTCAC-3' and 5'-GTGTTGCTT-GGTGTTTCCAC-3'; *Rank*: 5'-GCTGGCTACCACTGGAAGCTC-3' and 5'-GTGCAGTTGGTCCAAGGTTT-3'; *Spib1*: 5'-CTCTGAAC-CACCATGCTTGCT-3' and 5'-TCCTTCTGGGTACAAACAGCT-TAA-3'; *Spib2*: 5'-AGGGCGGCCCTGACAT-3' and 5'-TCCTTCT-GGGTACAAACAGCTTAA-3'; *Opg*: 5'-GGCGTTACCTGGAGATCG-3' and 5'-GAGAAGAACCATCTGGACATTT-3'; *Ccl19*: 5'-GCTAAT-GATCGGAAGACTG-3' and 5'-ACTCACATCGACTCTCTAGG-3'; *Col2*: 5'-AGAACAGCATCGCCTACCTG-3' and 5'-CTTGCCCACT-TACCAGTGT-3'; and *Csnb*: 5'-GGCACAGGTTGTTTCAGGCTT-3' and 5'-AAGGAAGGGTGTACTTGTCTG-3'.

**CpG methylation analysis.** Cell pellets were subjected to bisulfite treatment using the EZ DNA methylation-Direct kit (Zymo Research) according to the manufacturer's instructions. PCR was performed using treated DNA obtained from 200–300 cells. For bisulfite sequencing, PCR products were cloned into a pGEM-T easy vector (Promega), and >16 clones were sequenced using the ABI 3130 sequencer and Big-Dye terminator kit (Applied Biosystems).

**Preparation of tumor-infiltrating lymphocytes.** Tumors were minced with razor blades and digested in RPMI 1640 (Wako Pure Chemical Industries) containing 1 mg/ml collagenase D (Roche), 0.1 mg/ml DNase I, and 10% FBS for 1 h, with shaking. The remaining undigested fragments were passed through a needle. After addition of EDTA (final concentration: 10 mM), the cell suspension was filtered through a nylon mesh. The cells were collected and resuspended in 5 ml RPMI 1640 containing 45% Percoll and 10% FBS, and the mixture was layered on top of the same volume of 67.5% Percoll. After the cells were centrifuged at 800 g for 20 min at room temperature, the layer between 45% and 67.5% Percoll was collected.

**Statistical analysis.** P-values were calculated using Student's *t* test, Mann-Whitney *U* test with two-tailed distribution, and two-sample equivalent variance parameters. For statistical analysis of the tumor-free rate, the log-rank test was performed.

This work was supported by a Grant-in-Aid for Scientific Research from the Precursory Research for Embryonic Science and Technology (PRESTO) program of the Japan Science and Technology Agency (to T. Akiyama), grants from the Japanese Society for the Promotion of Science (to T. Akiyama), Takeda Science Foundation (to T. Akiyama), Princess Takamatsu Cancer Research Fund (to T. Akiyama), grants for Priority Area Research (to T. Akiyama and J.-i. Inoue), and a Grant-in-Aid for Challenging Exploratory Research (to T. Akiyama).

The authors declare no competing financial interests.

Submitted: 26 June 2014

Accepted: 17 October 2014

## REFERENCES

- Abramson, J., M. Giraud, C. Benoist, and D. Mathis. 2010. Aire's partners in the molecular control of immunological tolerance. *Cell*. 140:123–135. <http://dx.doi.org/10.1016/j.cell.2009.12.030>
- Aichinger, M., M. Hinterberger, and L. Klein. 2012. Probing gene function in thymic epithelial cells. *Eur. J. Cell Biol.* 91:24–30. <http://dx.doi.org/10.1016/j.ejcb.2011.01.005>
- Akiyama, T., S. Maeda, S. Yamane, K. Ogino, M. Kasai, F. Kajiura, M. Matsumoto, and J. Inoue. 2005. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. *Science*. 308:248–251. <http://dx.doi.org/10.1126/science.1105677>
- Akiyama, T., Y. Shimo, H. Yanai, J. Qin, D. Ohshima, Y. Maruyama, Y. Asaumi, J. Kitazawa, H. Takayanagi, J.M. Penninger, et al. 2008. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. *Immunity*. 29:423–437. <http://dx.doi.org/10.1016/j.immuni.2008.06.015>
- Akiyama, T., M. Shinzawa, and N. Akiyama. 2012a. RANKL-RANK interaction in immune regulatory systems. *World J. Orthop.* 3:142–150. <http://dx.doi.org/10.5312/wjo.v3.i9.142>
- Akiyama, T., M. Shinzawa, and N. Akiyama. 2012b. TNF receptor family signaling in the development and functions of medullary thymic epithelial cells. *Front. Immunol.* 3:278. <http://dx.doi.org/10.3389/fimmu.2012.00278>
- Anderson, G., and Y. Takahama. 2012. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. *Trends Immunol.* 33:256–263. <http://dx.doi.org/10.1016/j.it.2012.03.005>
- Anderson, G., E.J. Jenkinson, and H.R. Rodewald. 2009. A roadmap for thymic epithelial cell development. *Eur. J. Immunol.* 39:1694–1699. <http://dx.doi.org/10.1002/eji.200939379>
- Bartholdy, B., C. Du Roure, A. Bordon, D. Emslie, L.M. Corcoran, and P. Matthias. 2006. The Ets factor Spi-B is a direct critical target of the co-activator OBF-1. *Proc. Natl. Acad. Sci. USA*. 103:11665–11670. <http://dx.doi.org/10.1073/pnas.0509430103>
- Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. *Immunity*. 13:829–840. [http://dx.doi.org/10.1016/S1074-7613\(00\)00080-7](http://dx.doi.org/10.1016/S1074-7613(00)00080-7)
- Burkly, L., C. Hession, L. Ogata, C. Reilly, L.A. Marconi, D. Olson, R. Tizard, R. Cate, and D. Lo. 1995. Expression of reIB is required for the development of thymic medulla and dendritic cells. *Nature*. 373:531–536. <http://dx.doi.org/10.1038/373531a0>
- Chen, H.M., D.A. Gonzalez, H.S. Radomska, M.T. Voso, Z. Sun, P. Zhang, D.E. Zhang, and D.G. Tenen. 1998. Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor. *Gene*. 207:209–218. [http://dx.doi.org/10.1016/S0378-1119\(97\)00629-X](http://dx.doi.org/10.1016/S0378-1119(97)00629-X)
- Cowan, J.E., S.M. Parnell, K. Nakamura, J.H. Caamano, P.J. Lane, E.J. Jenkinson, W.E. Jenkinson, and G. Anderson. 2013. The thymic medulla is required for Foxp3<sup>+</sup> regulatory but not conventional CD4<sup>+</sup> thymocyte development. *J. Exp. Med.* 210:675–681. <http://dx.doi.org/10.1084/jem.20122070>
- Dontje, W., R. Schotte, T. Cupedo, M. Nagasawa, F. Scheeren, R. Gimeno, H. Spits, and B. Blom. 2006. Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B. *Blood*. 107:2446–2452. <http://dx.doi.org/10.1182/blood-2005-05-2090>

- Garrett-Sinha, L.A., G.H. Su, S. Rao, S. Kabak, Z. Hao, M.R. Clark, and M.C. Simon. 1999. PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction. *Immunity*. 10:399–408. [http://dx.doi.org/10.1016/S1074-7613\(00\)80040-0](http://dx.doi.org/10.1016/S1074-7613(00)80040-0)
- Gray, D., J. Abramson, C. Benoist, and D. Mathis. 2007. Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire. *J. Exp. Med.* 204:2521–2528. <http://dx.doi.org/10.1084/jem.20070795>
- Guerau-de-Arellano, M., M. Martinic, C. Benoist, and D. Mathis. 2009. Neonatal tolerance revisited: a perinatal window for Aire control of autoimmunity. *J. Exp. Med.* 206:1245–1252. <http://dx.doi.org/10.1084/jem.20090300>
- Hauri-Hohl, M., S. Zuklys, G.A. Holländer, and S.F. Ziegler. 2014. A regulatory role for TGF- $\beta$  signaling in the establishment and function of the thymic medulla. *Nat. Immunol.* 15:554–561. <http://dx.doi.org/10.1038/ni.2869>
- Heinz, S., C. Benner, N. Spann, E. Bertolino, Y.C. Lin, P. Laslo, J.X. Cheng, C. Murre, H. Singh, and C.K. Glass. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell.* 38:576–589. <http://dx.doi.org/10.1016/j.molcel.2010.05.004>
- Hikosaka, Y., T. Nitta, I. Ohigashi, K. Yano, N. Ishimaru, Y. Hayashi, M. Matsumoto, K. Matsuo, J.M. Penninger, H. Takayanagi, et al. 2008. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. *Immunity*. 29:438–450. <http://dx.doi.org/10.1016/j.immuni.2008.06.018>
- Hinterberger, M., M. Aichinger, O. Prazeres da Costa, D. Voehringer, R. Hoffmann, and L. Klein. 2010. Autonomous role of medullary thymic epithelial cells in central CD4<sup>+</sup> T cell tolerance. *Nat. Immunol.* 11:512–519. <http://dx.doi.org/10.1038/ni.1874>
- Jones, P.A., and S.B. Baylin. 2007. The epigenomics of cancer. *Cell*. 128:683–692. <http://dx.doi.org/10.1016/j.cell.2007.01.029>
- Kajiura, F., S. Sun, T. Nomura, K. Izumi, T. Ueno, Y. Bando, N. Kuroda, H. Han, Y. Li, A. Matsushima, et al. 2004. NF- $\kappa$ B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. *J. Immunol.* 172:2067–2075. <http://dx.doi.org/10.4049/jimmunol.172.4.2067>
- Kanaya, T., K. Hase, D. Takahashi, S. Fukuda, K. Hoshino, I. Sasaki, H. Hemmi, K.A. Knoop, N. Kumar, M. Sato, et al. 2012. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. *Nat. Immunol.* 13:729–736. <http://dx.doi.org/10.1038/ni.2352>
- Khan, I.S., M.L. Mouchess, M.L. Zhu, B. Conley, K.J. Fasano, Y. Hou, L. Fong, M.A. Su, and M.S. Anderson. 2014. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. *J. Exp. Med.* 211:761–768. <http://dx.doi.org/10.1084/jem.20131889>
- Klein, L., M. Hinterberger, G. Wirnsberger, and B. Kyewski. 2009. Antigen presentation in the thymus for positive selection and central tolerance induction. *Nat. Rev. Immunol.* 9:833–844. <http://dx.doi.org/10.1038/nri2669>
- Kyewski, B., and L. Klein. 2006. A central role for central tolerance. *Annu. Rev. Immunol.* 24:571–606. <http://dx.doi.org/10.1146/annurev.immunol.23.021704.115601>
- Lei, Y., A.M. Ripen, N. Ishimaru, I. Ohigashi, T. Nagasawa, L.T. Jeker, M.R. Bösl, G.A. Holländer, Y. Hayashi, R.W. Malefyt, et al. 2011. Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. *J. Exp. Med.* 208:383–394. <http://dx.doi.org/10.1084/jem.20102327>
- Leibbrandt, A., and J.M. Penninger. 2008. RANK/RANKL: regulators of immune responses and bone physiology. *Ann. N.Y. Acad. Sci.* 1143:123–150. <http://dx.doi.org/10.1196/annals.1443.016>
- Lio, C.W., and C.S. Hsieh. 2008. A two-step process for thymic regulatory T cell development. *Immunity*. 28:100–111. <http://dx.doi.org/10.1016/j.immuni.2007.11.021>
- Liu, X., P. Invernizzi, Y. Lu, R. Kosoy, Y. Lu, I. Bianchi, M. Podda, C. Xu, G. Xie, F. Macciardi, et al. 2010. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. *Nat. Genet.* 42:658–660. <http://dx.doi.org/10.1038/ng.627>
- Malchow, S., D.S. Leventhal, S. Nishi, B.I. Fischer, L. Shen, G.P. Paner, A.S. Amit, C. Kang, J.E. Geddes, J.P. Allison, et al. 2013. Aire-dependent thymic development of tumor-associated regulatory T cells. *Science*. 339:1219–1224. <http://dx.doi.org/10.1126/science.1233913>
- Mells, G.F., J.A. Floyd, K.I. Morley, H.J. Cordell, C.S. Franklin, S.Y. Shin, M.A. Heneghan, J.M. Neuberger, P.T. Donaldson, D.B. Day, et al. Wellcome Trust Case Control Consortium 3. 2011. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. *Nat. Genet.* 43:329–332. (published erratum appears in *Nat. Genet.* 2011. 43:1164) <http://dx.doi.org/10.1038/ng.789>
- Mizuno, A., N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, et al. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem. Biophys. Res. Commun.* 247:610–615. <http://dx.doi.org/10.1006/bbrc.1998.8697>
- Ohshima, D., J. Qin, H. Konno, A. Hirotsawa, T. Shiraiishi, H. Yanai, Y. Shimo, M. Shinzawa, N. Akiyama, R. Yamashita, et al. 2011. RANK signaling induces interferon-stimulated genes in the fetal thymic stroma. *Biochem. Biophys. Res. Commun.* 408:530–536. <http://dx.doi.org/10.1016/j.bbrc.2011.04.049>
- Ray, D., R. Bosselut, J. Ghysdael, M.G. Mattei, A. Tavitian, and F. Moreau-Gachelin. 1992. Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-1/PU.1. *Mol. Cell. Biol.* 12:4297–4304.
- Rossi, S.W., M.Y. Kim, A. Leibbrandt, S.M. Parnell, W.E. Jenkinson, S.H. Glanville, F.M. McConnell, H.S. Scott, J.M. Penninger, E.J. Jenkinson, et al. 2007. RANK signals from CD4<sup>+</sup> inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. *J. Exp. Med.* 204:1267–1272. <http://dx.doi.org/10.1084/jem.20062497>
- Sasaki, I., K. Hoshino, T. Sugiyama, C. Yamazaki, T. Yano, A. Iizuka, H. Hemmi, T. Tanaka, M. Saito, M. Sugiyama, et al. 2012. Spi-B is critical for plasmacytoid dendritic cell function and development. *Blood*. 120:4733–4743. <http://dx.doi.org/10.1182/blood-2012-06-436527>
- Schotte, R., M. Nagasawa, K. Weijer, H. Spits, and B. Blom. 2004. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. *J. Exp. Med.* 200:1503–1509. <http://dx.doi.org/10.1084/jem.20041231>
- Shinkura, R., K. Kitada, F. Matsuda, K. Tashiro, K. Ikuta, M. Suzuki, K. Kogishi, T. Serikawa, and T. Honjo. 1999. Alymphoplasia is caused by a point mutation in the mouse gene encoding NF- $\kappa$ B-inducing kinase. *Nat. Genet.* 22:74–77. <http://dx.doi.org/10.1038/8780>
- Sun, S.C. 2012. The noncanonical NF- $\kappa$ B pathway. *Immunol. Rev.* 246:125–140. <http://dx.doi.org/10.1111/j.1600-065X.2011.01088.x>
- Thu, Y.M., and A. Richmond. 2010. NF- $\kappa$ B inducing kinase: a key regulator in the immune system and in cancer. *Cytokine Growth Factor Rev.* 21:213–226. <http://dx.doi.org/10.1016/j.cytogfr.2010.06.002>
- Träger, U., S. Sierro, G. Djordjevic, B. Bouzo, S. Khandwala, A. Meloni, M. Mortensen, and A.K. Simon. 2012. The immune response to melanoma is limited by thymic selection of self-antigens. *PLoS ONE*. 7:e35005. <http://dx.doi.org/10.1371/journal.pone.0035005>
- Weih, F., D. Carrasco, S.K. Durham, D.S. Barton, C.A. Rizzo, R.P. Ryseck, S.A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF- $\kappa$ B/Rel family. *Cell*. 80:331–340. [http://dx.doi.org/10.1016/0092-8674\(95\)90416-6](http://dx.doi.org/10.1016/0092-8674(95)90416-6)
- Yagi, S., K. Hirabayashi, S. Sato, W. Li, Y. Takahashi, T. Hirakawa, G. Wu, N. Hattori, N. Hattori, J. Ohgane, et al. 2008. DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) in mouse promoter regions demonstrating tissue-specific gene expression. *Genome Res.* 18:1969–1978. <http://dx.doi.org/10.1101/gr.074070.107>
- Zhu, M.L., A. Nagavalli, and M.A. Su. 2013. Aire deficiency promotes TRP-1-specific immune rejection of melanoma. *Cancer Res.* 73:2104–2116. <http://dx.doi.org/10.1158/0008-5472.CAN-12-3781>